Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children59510.24287/1726-1708-2022-21-1-94-102CLINICAL OBSERVATIONSКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯTreatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin’s lymphoma (gray zone lymphoma) in children and young adults: a case seriesЛечение неклассифицируемой В-клеточной лимфомы с промежуточными признаками диффузной крупноклеточной В-клеточной лимфомы и классической лимфомы Ходжкина (лимфома серой зоны) у детей и молодых взрослых. Описание серии случаевhttps://orcid.org/0000-0002-2574-1636VolchkovE. V.ВолчковЕ. В.
Russian Federation

Egor V. Volchkov, a hematologist at the Department of Oncohematology

1 Samory Mashela St., 117997, Moscow 

Волчков Егор Васильевич, врач-гематолог отделения онкогематологии

117997, Москва, ул. Саморы Машела, 1

volchcov.egor@yandex.ruhttps://orcid.org/0000-0002-9921-5620SenchenkoM. A.СенченкоМ. А.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0003-3664-2876AbramovD. S.АбрамовД. С.
Russian Federation

Moscow

Москва

BiyachuevE. R.БиячуевЭ. Р.
Russian Federation

Moscow

Москва

PrudnikovaO. N.ПрудниковаО. Н.
Russian Federation

Omsk

Омск

https://orcid.org/0000-0001-7732-8184KonovalovD. M.КоноваловД. М.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-4779-1896MyakovaN. V.МяковаН. В.
Russian Federation

Moscow

Москва

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииS.P. Botkin City Clinical Hospital of Moscow Department of HealthГБУЗ Городская клиническая больница им. С.П. Боткина Департамента здравоохранения г. МосквыClinical Oncological DispensaryБУЗ ОО «Клинический онкологический диспансер»30032022211941022903202229032022Copyright ©; 2022, «D. Rogachev NMRCPHOI»Copyright ©; 2022, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2022«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/595

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin’s lymphoma (cHL) is a rare malignant disease that develops from mature B cells. This disease was first recognized as a distinct entity in 2008. It is most common in the 20 to 40 age group and rare in children. Currently, there are no clear criteria for diagnosis and standard therapy for such patients. According to the literature, it is possible to use treatment regimens applied for both aggressive B-cell lymphomas and Hodgkin's lymphoma. The addition of anti-CD20/CD30 targeted agent to standard therapy may be effective, given the expression of these markers by tumor cells. In this article, we present the clinical and morphological characteristics of patients with unclassifiable B-cell lymphoma with features intermediate between DLBCL and cHL, diagnosed at our center, including 4 patients at the onset of the disease in childhood. Patients and/or their legal representatives have consented to the use of information, including photographs, in scientific research and publications.

В-клеточная лимфома неклассифицируемая (ВКЛН), занимающая промежуточное положение между диффузной крупноклеточной В-клеточной лимфомой (ДКБКЛ) и классической лимфомой Ходжкина (ЛХ), – редкое злокачественное заболевание, развивающееся из зрелых В-клеток. Впервые данное заболевание выделено в отдельную нозологию в 2008 г. Наиболее часто встречается в возрастной группе от 20 до 40 лет и довольно редко у детей. В настоящий момент не существует четких критериев постановки диагноза и стандартов терапии для таких пациентов. По литературным данным, возможно использование терапевтических схем, применяемых для лечения как агрессивных В-клеточных лимфом, так и ЛХ. Также возможно применение анти-CD20-/CD30-направленной терапии, учитывая экспрессию опухолевыми клетками данных маркеров. В настоящей статье мы приводим клинико-морфологическую характеристику больных с диагнозом ВКЛН с промежуточными признаками ДКБКЛ и классической ЛХ, установленным в нашем Центре, в том числе у 4 пациентов с дебютом заболевания в детском возрасте. Пациенты и/или их законные представители дали согласие на использование информации, в том числе фотографий, в научных исследованиях и публикациях.

mediastinal gray zone lymphomagray zone lymphomadiffuse large B-cell lymphomaclassical Hodgkin’s lymphomaprimary mediastinal large B cell lymphomaмедиастинальная лимфома серой зонылимфома серой зоныдиффузная крупноклеточная В-клеточная лимфомаклассическая лимфома Ходжкинапервичная медиастинальная В-клеточная лимфома1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S., Thiele J., et al. Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Revised 4th ed. Vol. 2. Lyon: IARC Press; 2017.Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S., Thiele J., et al. Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Revised 4th ed. Vol. 2. Lyon: IARC Press; 2017.2. García J.F., Mollejo M., Fraga M., Forteza J., Muniesa J.A., Pérez-Guillermo M., et al. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005; 47 (1): 101–10. DOI: 10.1111/j.1365-2559.2005.02175.xGarcía J.F., Mollejo M., Fraga M., Forteza J., Muniesa J.A., Pérez-Guillermo M., et al. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005; 47 (1): 101–10. DOI: 10.1111/j.1365-2559.2005.02175.x3. Traverse-Glehen A., Pittaluga S., Gaulard P., Sorbara L., Alonso M.A., Raffeld M., et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005; 29 (11): 1411–21. DOI: 10.1097/01.pas.0000180856.74572.73Traverse-Glehen A., Pittaluga S., Gaulard P., Sorbara L., Alonso M.A., Raffeld M., et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005; 29 (11): 1411–21. DOI: 10.1097/01.pas.0000180856.74572.734. Oschlies I., Burkhardt B., Salaverria I., Rosenwald A., d'Amore E.S.G., Szczepanowski M., et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011; 96 (2): 262–8. DOI: 10.3324/haematol.2010.030809Oschlies I., Burkhardt B., Salaverria I., Rosenwald A., d'Amore E.S.G., Szczepanowski M., et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011; 96 (2): 262–8. DOI: 10.3324/haematol.2010.0308095. Sarkozy C., Molina T., Ghesquières H., Michallet A., Dupuis J., Damotte D., et al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica 2017; 102 (1): 150–9. DOI: 10.3324/haematol.2016.152256Sarkozy C., Molina T., Ghesquières H., Michallet A., Dupuis J., Damotte D., et al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica 2017; 102 (1): 150–9. DOI: 10.3324/haematol.2016.1522566. Pilichowska M., Pittaluga S., Ferry A., Hemminger J., Chang H., Kanakry J.A., et al. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv 2017; 1 (26): 2600–9. DOI: 10.1182/bloodadvances.2017009472Pilichowska M., Pittaluga S., Ferry A., Hemminger J., Chang H., Kanakry J.A., et al. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv 2017; 1 (26): 2600–9. DOI: 10.1182/bloodadvances.20170094727. Browne P., Petrosyan K., Hernandez A., Chan A. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003; 120 (5): 767–77. DOI: 10.1309/YCH8-DWUFFQBK-GPVBBrowne P., Petrosyan K., Hernandez A., Chan A. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003; 120 (5): 767–77. DOI: 10.1309/YCH8-DWUFFQBK-GPVB8. Re D., Müschen M., Ahmadi T., Wickenhauser C., Staratschek-Jox A., Holtick U., et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res 2001; 61 (5): 2080–4. PMID: 11280769.Re D., Müschen M., Ahmadi T., Wickenhauser C., Staratschek-Jox A., Holtick U., et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res 2001; 61 (5): 2080–4. PMID: 11280769.9. Bledsoe R., Redd A., Hasserjian P., Soumerai D., Nishino H.T., Boyer D.F., et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol 2016; 91 (10): E436–41. DOI: 10.1002/ajh.24485Bledsoe R., Redd A., Hasserjian P., Soumerai D., Nishino H.T., Boyer D.F., et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol 2016; 91 (10): E436–41. DOI: 10.1002/ajh.2448510. Wilson H., Pittaluga S., Nicolae A., Camphausen K., Shovlin M., Steinberg S.M., et al. A prospective study of mediastinal gray-zone lymphoma. Blood 2014; 124 (10): 1563–9. DOI: 10.1182/blood-2014-03-564906Wilson H., Pittaluga S., Nicolae A., Camphausen K., Shovlin M., Steinberg S.M., et al. A prospective study of mediastinal gray-zone lymphoma. Blood 2014; 124 (10): 1563–9. DOI: 10.1182/blood-2014-03-56490611. Kritharis A., Pilichowska M., Evens A.M. How I manage patients with grey zone lymphoma. Br J Haematol 2016; 174 (3): 345–50. DOI: 10.1111/bjh.14174Kritharis A., Pilichowska M., Evens A.M. How I manage patients with grey zone lymphoma. Br J Haematol 2016; 174 (3): 345–50. DOI: 10.1111/bjh.1417412. Evens M., Kanakry A., Sehn H., Kritharis A., Feldman T., Kroll A., et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol 2015; 90 (9): 778–83. DOI: 10.1002/ajh.24082Evens M., Kanakry A., Sehn H., Kritharis A., Feldman T., Kroll A., et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol 2015; 90 (9): 778–83. DOI: 10.1002/ajh.2408213. Liang X., Greffe B., Cook B., Giller R., Graham D.K., McGranahan A.N., et al. Gray zone lymphomas in pediatric patients. Pediatr Dev Pathol 2011; 14 (1): 57–63. DOI: 10.2350/09-10-0724- CR.1Liang X., Greffe B., Cook B., Giller R., Graham D.K., McGranahan A.N., et al. Gray zone lymphomas in pediatric patients. Pediatr Dev Pathol 2011; 14 (1): 57–63. DOI: 10.2350/09-10-0724- CR.114. Perwein T., Lackner H., Ebetsberger-Dachs G., Beham-Schmid C., Zach K., Tamesberger M., et al. Management of children and adolescents with gray zone lymphoma: A case series. Pediatr Blood Cancer 2020; 67 (5): e28206. DOI: 10.1002/pbc.28206Perwein T., Lackner H., Ebetsberger-Dachs G., Beham-Schmid C., Zach K., Tamesberger M., et al. Management of children and adolescents with gray zone lymphoma: A case series. Pediatr Blood Cancer 2020; 67 (5): e28206. DOI: 10.1002/pbc.2820615. Сагоян Г.Б., Андержанова Л.Х., Дьяконова Ю.Ю., Абрамов Д.С., Щербаков А.П., Мякова Н.В. В-клеточная лимфома неклассифицируемая с промежуточными признаками между диффузной крупноклеточной В-клеточной лимфомой и лимфомой Ходжкина. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2019; 18 (1): 88‒95. DOI: 10.24287/1726-1708-2019-18-1-88-95Сагоян Г.Б., Андержанова Л.Х., Дьяконова Ю.Ю., Абрамов Д.С., Щербаков А.П., Мякова Н.В. В-клеточная лимфома неклассифицируемая с промежуточными признаками между диффузной крупноклеточной В-клеточной лимфомой и лимфомой Ходжкина. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2019; 18 (1): 88‒95. DOI: 10.24287/1726-1708-2019-18-1-88-9516. Von Wasielewski R., Mengel M., Fischer R., Hansmann L., Hübner K., Franklin J., et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997; 151 (4): 1123–30. PMID: 9327746.Von Wasielewski R., Mengel M., Fischer R., Hansmann L., Hübner K., Franklin J., et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997; 151 (4): 1123–30. PMID: 9327746.17. Portlock S., Donnelly B., Qin J., Straus D., Yahalom J., Zelenetz A., et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol 2004; 125 (6): 701–8. DOI: 10.1111/j.1365-2141.2004.04964.xPortlock S., Donnelly B., Qin J., Straus D., Yahalom J., Zelenetz A., et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol 2004; 125 (6): 701–8. DOI: 10.1111/j.1365-2141.2004.04964.x18. Pileri A., Gaidano G., Zinzani P.L., Falini B., Gaulard P., Zucca E., et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003; 162 (1): 243–53. DOI: 10.1016/s0002-9440(10)63815-1Pileri A., Gaidano G., Zinzani P.L., Falini B., Gaulard P., Zucca E., et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003; 162 (1): 243–53. DOI: 10.1016/s0002-9440(10)63815-119. Higgins P., Warnke A. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 1999; 112 (2): 241–7. DOI: 10.1093/ajcp/112.2.241Higgins P., Warnke A. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 1999; 112 (2): 241–7. DOI: 10.1093/ajcp/112.2.24120. Gong X., Wang Z., Liu C., Li X., Lu T.-X., Liang J.-H., et al. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. J Clin Pathol 2018; 71 (9): 795–801. DOI: 10.1136/jclinpath-2018-205039Gong X., Wang Z., Liu C., Li X., Lu T.-X., Liang J.-H., et al. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. J Clin Pathol 2018; 71 (9): 795–801. DOI: 10.1136/jclinpath-2018-20503921. Castillo J., Chavez C., Hernandez-Ilizaliturri J., Montes-Moreno S. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol 2015; 8 (3): 343–54. DOI: 10.1586/17474086.2015.1007862Castillo J., Chavez C., Hernandez-Ilizaliturri J., Montes-Moreno S. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol 2015; 8 (3): 343–54. DOI: 10.1586/17474086.2015.100786222. Starr A., Kwon H., Kallakury B. Epstein–Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. Int J Surg Pathol 2019; 27 (1): 98–101. DOI: 10.1177/1066896918784669Starr A., Kwon H., Kallakury B. Epstein–Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. Int J Surg Pathol 2019; 27 (1): 98–101. DOI: 10.1177/106689691878466923. Calvo R., Traverse-Glehen A., Pittaluga S., Jaffe S. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol 2004; 11 (5): 227–38. DOI: 10.1097/01.pap.0000138144.11635.f8Calvo R., Traverse-Glehen A., Pittaluga S., Jaffe S. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol 2004; 11 (5): 227–38. DOI: 10.1097/01.pap.0000138144.11635.f824. Grant C., Dunleavy K., Eberle F.C., Pittaluga S., Wilson W.H., Jaffe E.S. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep 2011; 6 (3): 157– 63. DOI: 10.1007/s11899-011-0090-1Grant C., Dunleavy K., Eberle F.C., Pittaluga S., Wilson W.H., Jaffe E.S. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep 2011; 6 (3): 157– 63. DOI: 10.1007/s11899-011-0090-125. Sarkozy C., Chong L., Takata K., Elizabeth A., Miyata-Takata T., Duns G., et al. Gene expression profiling of gray zone lymphoma. Blood Adv 2020; 4 (11): 2523–35. DOI: 10.1182/bloodadvances.2020001923Sarkozy C., Chong L., Takata K., Elizabeth A., Miyata-Takata T., Duns G., et al. Gene expression profiling of gray zone lymphoma. Blood Adv 2020; 4 (11): 2523–35. DOI: 10.1182/bloodadvances.2020001923